NICE backs KEYTRUDA combination for advanced endometrial cancer

New first-line option for patients with pMMR and dMMR tumours in England

NICE has recommended KEYTRUDA (pembrolizumab) with carboplatin and paclitaxel chemotherapy as a first-line treatment for adults with untreated primary advanced or recurrent endometrial cancer in England.

The decision includes patients with mismatch repair proficient (pMMR) and mismatch repair deficient (dMMR) tumours. Until now, only those with dMMR tumours had access to immunotherapy in combination with chemotherapy.

Endometrial cancer is the most common type of womb cancer and the most prevalent gynaecological…